BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

Penn, Regeneron on AAV-encoded REGN-COV2A James Wilson-led University of Pennsylvania team is developing a gene therapy form of casirivimab/imdevimab (REGN-COV2) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). The collaboration is based on the potential for a single, intranasal...
BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy communication. Krystal Biotech Inc. (NASDAQ:KRYS) said...
BioCentury | Oct 2, 2020

From Termeer to scuttled Allergan deal, Lysosomal’s winding road continues with Bial takeout

A takeout by Bial brings to an end Lysosomal’s search for a partner to advance its Parkinson’s programs after Allergan turned down its option to acquire the biotech last year.  Portugal-based Bial...
BioCentury | Aug 24, 2020
Politics, Policy & Law

Angered by NIH’s Collins, Trump misfires and hits FDA Commissioner Hahn

President Donald Trump’s recent attacks on FDA were prompted by Trump’s anger at NIH Director Francis Collins for delaying authorization of COVID-19 convalescent plasma, individuals who have been in close touch with the White House...
BioCentury | Jul 28, 2020
Politics, Policy & Law

Biopharma industry accelerates attacks on Trump

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling...
BioCentury | Jul 7, 2020
Politics, Policy & Law

FDA credibility on the line with White House pressure on hydroxychloroquine

Demands from President Donald Trump that FDA issue a second Emergency Use Authorization for the use of hydroxychloroquine to treat COVID-19 test agency chief Stephen Hahn’s commitment to public health again, and pose challenges to...
BioCentury | Jul 6, 2020
Politics, Policy & Law

Trump to sign drug pricing order, chief of staff says

President Donald Trump will sign executive orders this week on drug pricing, bringing manufacturing back to the U.S., and immigration, White House Chief of Staff Mark Meadows said Monday in a television interview on Fox...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Apr 23, 2020

Nitrome emerges with $38M series A, platform for age-related diseases

Nitrome debuted Tuesday with a $38 million series A round, a platform targeting a newly identified class of enzymes dubbed nitrases and a lead program to treat Parkinson’s disease. Sofinnova Partners and AbbVie Ventures co-led...
BioCentury | Apr 2, 2020
Distillery Therapeutics

CDC42BPA inhibition for high-grade serous ovarian carcinoma

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Inhibition of CDC42BPA alone or in combination with carboplatin and PAK1 inhibition could treat high-grade serous ovarian carcinoma (HGSOC). Among 594 patient tumors, 44% of the samples had genomic...
Items per page:
1 - 10 of 290